Stemline Therapeutics (STML) Stock Rating Lowered by BidaskClub

Stemline Therapeutics (NASDAQ:STML) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Thursday.

STML has been the topic of a number of other reports. HC Wainwright increased their price objective on shares of Stemline Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, November 1st. ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Finally, Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $33.40.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at $14.52 on Thursday. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $15.95.

Institutional investors have recently modified their holdings of the company. Voya Investment Management LLC acquired a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $102,000. Nationwide Fund Advisors boosted its holdings in shares of Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 855 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $147,000. Alliancebernstein L.P. acquired a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $178,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 5,522 shares in the last quarter. Institutional investors and hedge funds own 50.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics (STML) Stock Rating Lowered by BidaskClub” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/07/stemline-therapeutics-stml-stock-rating-lowered-by-bidaskclub.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

What are top analysts saying about Stemline Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit